News

— SpyBiotech’s lead program is targeting human cytomegalovirus (HCMV) — Oxford, UK and Cambridge, MA (December 7, 2023) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, today announced that the first subject has been dosed with SPYVLP01, a candidate vaccine targeting human cytomegalovirus […]

— SpyBiotech’s lead program to target HCMV — Oxford, UK and Cambridge, MA (September 20, 2023) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced that the company has filed a clinical trial application (CTA) with the U.K. Medicines and Healthcare products Regulatory

— Funding from the Bill & Melinda Gates Foundation will support development of next generation pan-SARS-CoV-2 and pan-sarbecovirus vaccines — Oxford, UK and Cambridge, MA (March 20, 2023) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has received a grant of $4,094,561 from

Oxford, UK and Cambridge, MA (February 13, 2023) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Eddie Gray, MBA, as Chairman of its Board of Directors. Gray joins the Board as an independent director. Gray has over forty years of global

— Novel Vaccine Company Expands Leadership Team and Establishes US Presence — Oxford, UK and Cambridge, MA (July 11, 2022) — SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the

A research paper demonstrating the potential of SpyBiotech’s SpyCatcher/SpyTag vaccine platform has been published in Science Advances. A Covid-19 vaccine being developed with SpyBiotech’s technology elicited a strong immune response in non-human primates, showing titres of neutralising antibodies (>104) that were above the range of protection provided by other licensed vaccines in pre-clinical studies. The

Oxford, UK, 16 November 2021: SpyBiotech, a biotechnology company with a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, today announces the appointment of Simon Jones as VP of Finance and Operations, and the expansion of its scientific team with four new hires. Simon takes up the permanent position of VP Finance

A study from Scripps using SpyTag/SpyCatcher technology shows that the receptor-binding domain and stabilized SARS-CoV-2 spike displayed on ferritin nanoparticles as vaccine antigens, elicited potent immune responses. Click link here for the paper (14 Sept, 2020)

New technology platform helps accelerate vaccine generation SpyBiotech has today been featured in The Guardian’s Value of Vaccines supplement, discussing the technological solutions we have developed to accelerate vaccine generation for COVID-19 variants and potentially a range of other diseases for which there are no approved treatments. “The COVID-19 vaccine uses SpyBiotech’s unique protein “superglue”

Oxford, U.K., March 8, 2021: SpyBiotech, a British biotechnology company with a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, today announces the appointments of Dan Menichella as an independent, non-executive director and Norman Begg as a scientific advisor. Mr Menichella brings with him over 20 years of executive and leadership experience